Sponsored by
Rep. Craig, Angie [D-MN-2]
ID: C001119
Follow the money
The bill
HR. 6255, 119th Congress — read as touching Pharmaceuticals.
The sponsor
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
27 itemised contributions to this sponsor, pulled from FEC filings.
Track this bill's progress through the legislative process
Latest Action
Invalid Date
📍 Current Status
Next: The bill will be reviewed by relevant committees who will debate, amend, and vote on it.
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
No summary available
Rep. Craig, Angie [D-MN-2]
Congress 119 • 2024 Election Cycle
No PAC contributions found
No committee contributions found
Hub layout: Politicians in center, donors arranged by type in rings around them.
Showing 56 nodes and 27 connections (70 secondary connections hidden)
Total contributions: $152,000
Showing top 22 donors by contribution amount
Which industries are materially affected by specific provisions in this bill. 3 harmed.
Section 2(a) and (b) impose cost-sharing caps on insulin products, limiting what health plans can charge patients, which reduces revenue for insulin manufacturers (pharmaceuticals).
Sections 2(a), (b), and (c) require health insurers to cover insulin with no deductible and capped cost-sharing, increasing their financial liability for insulin claims.
By limiting cost-sharing for insulin, the bill may reduce revenue from insulin-related services in hospital outpatient pharmacies or infusion centers, though impact is indirect.
For each industry this bill affects, here's what the sponsor (Rep. Craig, Angie [D-MN-2])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.